Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89)
McKesson Packaging Services a business unit of McKesson Corporation
LOSARTAN POTASSIUM
LOSARTAN POTASSIUM 25 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
LOSARTAN POTASSIUM- LOSARTAN POTASSIUM TABLET, FILM COATED MCKESSON PACKAGING SERVICES A BUSINESS UNIT OF MCKESSON CORPORATION ---------- LOSARTAN POTASSIUM TABLETS, USP 25 MG, 50 MG & 100 MG RX ONLY OCTOBER 2011 USE IN PREGNANCY WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is detected, losartan potassium should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality. DESCRIPTION Losartan potassium, USP is an angiotensin II receptor (type AT ) antagonist. Losartan potassium, USP, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[_p_-(_o_-1_H_-tetrazol-5- ylphenyl)benzyl]imidazole-5-methanol, monopotassium salt. Its molecular formula is C H ClKN O, and its structural formula is: Losartan potassium, USP is a white to off-white free-flowing crystalline powder with a molecular weight of 461.00. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan. Losartan potassium, USP is available as tablets for oral administration containing either 25 mg, 50 mg or 100 mg of losartan potassium, USP and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, povidone, propylene glycol, talc, titanium dioxide. Losartan potassium tablets, USP 25 mg, 50 mg and 100 mg contain potassium in the following amounts: 2.12 mg (0.054 mEq), 4.24 mg (0.108 mEq) and 8.48 mg (0.216 mEq), respectively. 1 22 22 6 CLINICAL PHARMACOLOGY MECHANISM OF ACTION Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important com Izlasiet visu dokumentu